TY - JOUR
T1 - Multifunctional Nanoprobe for the Delivery of Therapeutic siRNA and Real-Time Molecular Imaging of Parkinson's Disease Biomarkers
AU - Li, Rui
AU - Li, Yi
AU - Mu, Mingdao
AU - Yang, Boguang
AU - Chen, Xiaoyu
AU - Lee, Wayne Yuk Wai
AU - Ke, Ya
AU - Yung, Wing Ho
AU - Tang, Ben Zhong
AU - Bian, Liming
PY - 2021/3/17
Y1 - 2021/3/17
N2 - Parkinson's disease (PD) has been recently associated with the excessive expression of matrix metalloproteinase 3 (MMP3). One of the major challenges in treating PD is to effectively detect and inhibit the early MMP3 activities to relieve the neural stress and inflammation responses. Previously, numerous upconversion nanoparticle (UCNP)-based nanoprobes have been designed for the detection of biomarkers in neurodegenerative diseases. To further improve the performance of the conventional nanoprobes, we introduced novel reporting units and integrated the therapeutic reagents to fabricate a theragnostic platform for PD and other neurodegenerative diseases. Here, we designed a multifunctional UCNP/aggregation-induced emission luminogen (AIEgen)-based nanoprobe to effectively detect the time-lapse MMP3 activities in the inflammatory catecholaminergic SH-SY5Y cells and simultaneously deliver the MMP3-siRNA into the stressed catecholaminergic SH-SY5Y cells, inhibiting the MMP3-induced inflammatory neural responses. The unique features of our UCNP/AIEgen-based nanoprobe platform shed light on the development of a novel theragnostic probe for the early diagnosis and cure of neurodegenerative diseases. © 2021 American Chemical Society.
AB - Parkinson's disease (PD) has been recently associated with the excessive expression of matrix metalloproteinase 3 (MMP3). One of the major challenges in treating PD is to effectively detect and inhibit the early MMP3 activities to relieve the neural stress and inflammation responses. Previously, numerous upconversion nanoparticle (UCNP)-based nanoprobes have been designed for the detection of biomarkers in neurodegenerative diseases. To further improve the performance of the conventional nanoprobes, we introduced novel reporting units and integrated the therapeutic reagents to fabricate a theragnostic platform for PD and other neurodegenerative diseases. Here, we designed a multifunctional UCNP/aggregation-induced emission luminogen (AIEgen)-based nanoprobe to effectively detect the time-lapse MMP3 activities in the inflammatory catecholaminergic SH-SY5Y cells and simultaneously deliver the MMP3-siRNA into the stressed catecholaminergic SH-SY5Y cells, inhibiting the MMP3-induced inflammatory neural responses. The unique features of our UCNP/AIEgen-based nanoprobe platform shed light on the development of a novel theragnostic probe for the early diagnosis and cure of neurodegenerative diseases. © 2021 American Chemical Society.
KW - aggregation-induced emission
KW - biomarker-triggered nanoprobe
KW - metalloproteinase 3
KW - Parkinson's disease
KW - upconversion nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85103228923&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85103228923&origin=recordpage
U2 - 10.1021/acsami.0c22112
DO - 10.1021/acsami.0c22112
M3 - RGC 21 - Publication in refereed journal
C2 - 33683858
SN - 1944-8244
VL - 13
SP - 11609
EP - 11620
JO - ACS Applied Materials and Interfaces
JF - ACS Applied Materials and Interfaces
IS - 10
ER -
